Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat.

MLA

Rahaghi, Franck F., et al. “Delphi Consensus Recommendation for Optimization of Pulmonary Hypertension Therapy Focusing on Switching from a Phosphodiesterase 5 Inhibitor to Riociguat.” Pulmonary Circulation, vol. 12, no. 2, Apr. 2022, p. e12055. EBSCOhost, https://doi.org/10.1002/pul2.12055.

APA

Rahaghi, F. F., Balasubramanian, V. P., Bourge, R. C., Burger, C. D., Chakinala, M. M., Eggert, M. S., Elwing, J. M., Feldman, J., King, C., Klinger, J. R., Mathai, S. C., McConnell, J. W., Palevsky, H. I., Restrepo-Jaramillo, R., Safdar, Z., Sager, J. S., Sood, N., Sulica, R., White, R. J., & Hill, N. S. (2022). Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat. Pulmonary Circulation, 12(2), e12055. https://doi.org/10.1002/pul2.12055

Chicago

Rahaghi, Franck F, Vijay P Balasubramanian, Robert C Bourge, Charles D Burger, Murali M Chakinala, Michael S Eggert, Jean M Elwing, et al. 2022. “Delphi Consensus Recommendation for Optimization of Pulmonary Hypertension Therapy Focusing on Switching from a Phosphodiesterase 5 Inhibitor to Riociguat.” Pulmonary Circulation 12 (2): e12055. doi:10.1002/pul2.12055.